Analog Devices Appoints Dr. Laurie H. Glimcher to Board of Directors
August 19, 2020 | Business WireEstimated reading time: 2 minutes
Analog Devices, Inc. announced the appointment of Dr. Laurie H. Glimcher, MD, to the Board of Directors as an independent director, effective immediately. Dr. Glimcher is currently a Professor of Medicine at Harvard Medical School and the President and Chief Executive Officer of the Dana-Farber Cancer Institute.
Dr. Glimcher’s appointment expands the Board to 11 directors, nine of whom are independent. She will be a member of the Board’s Compensation Committee.
“We are excited to have Laurie join the ADI Board as we continue to invest and develop innovative healthcare solutions for our customers,” said Ray Stata, ADI Chairman of the Board. “Laurie is a distinguished immunologist with extensive experience working in both private and public settings to advance research, medical education and health policy. In addition, Laurie is a pioneering mentor and strong advocate promoting women’s role in science. The insights she has gained over her medical career will be of great benefit to ADI as we aim to accelerate the growth of our healthcare business.”
Dr. Glimcher speaks nationally and internationally on cancer, immunology, skeletal biology, and translational medicine, and has contributed more than 350 scholarly articles and papers to the medical literature. She also currently serves on the Board of Directors at GlaxoSmithKline Pharmaceutical Corporation.
In addition to a number of senior leadership roles held at both Harvard Medical School and Harvard School of Public Health from 1982 to present, she has also served as the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. She is a member of the Board of Trustees at the Dana-Farber Cancer Institute and a member of the US National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences and the American Philosophical Society. She previously served on the Board of Directors of Bristol-Myers Squibb Pharmaceutical Corporation and Waters Corporation.
She is also the recipient of many awards and honors. In 2018, she received the American Association of Immunologists Lifetime Achievement Award; the Indiana University School of Medicine's Steven C. Beering Award for outstanding research contributions to advancement of biomedical or clinical science; and the L'Oréal-UNESCO Award for Women in Science. She has also received the 2017 George M. Kober Medal and the 2017 Award for Distinguished Research in the Biomedical Sciences from the Association of American Medical Colleges (AAMC).
Dr. Glimcher is a magna cum laude graduate of Radcliffe College, and holds an MD degree cum laude from Harvard Medical School.
Suggested Items
Absolute EMS Completes ISO 13485:2016 Recertification, Strengthening Commitment to Medical Device Quality Systems
03/25/2024 | Absolute EMS, Inc.Absolute EMS, Inc., an award-winning EMS provider of turnkey contract manufacturing services, proudly announces the successful completion of its ISO 13485:2016 audit, reaffirming its commitment to excellence in medical device manufacturing.
IMI Signs Memorandum with RRR Manufacturing PTY Ltd.
03/12/2024 | IMIIntegrated Micro-Electronics, Inc. (IMI), A memorandum of understanding (MOU) was recently signed between Integrated Micro Electronics Inc. and RRR Manufacturing PTY Ltd for the manufacture of portable automated external defibrillator solutions branded as CellAED. IMI will manufacture the full box build for the medical device that will be distributed both locally and abroad.
NEOTech Implements Advanced Technology for Enhanced Barcode Tracking in High-Tech Medical Device Production
03/08/2024 | NEOTechNEOTech, a leading provider of electronic manufacturing services (EMS), design engineering, and supply chain solutions in the high-tech industrial, medical device, and aerospace/defense markets, is thrilled to announce the implementation of improved technology to further enhance barcode tracking in the production of high-tech medical devices.
Cicor Acquires Evolution Medtec Srl, Strengthens Engineering Capabilities in Medtech Sector
02/28/2024 | Cicor Technologies Ltd.The Cicor Group has acquired 100% of the shares of the Romanian engineering company Evolution Medtec Srl and is further expanding its engineering capabilities in the medical technology sector.
Happy’s Tech Talk #25: Lab-on-PCBs for Medical Diagnosis
02/21/2024 | Happy Holden -- Column: Happy’s Tech TalkCOVID-19 created a rush for simple and quick medical diagnostic tests for the public. Biomedical MEMS (bioMEMS) have emerged as a subset of MEMS devices for applications in biomedical research and medical microdevices, with an emphasis on mechanical parts and microfabrication technologies. Applications include disease detection, chemical monitoring, and drug delivery. There has been rapid market growth for bioMEMS technologies, and many bioMEMS devices are already commercially available. There is great potential for large-scale commercialization of microfluidic-based LoC and LoPCB technologies.